Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benza

Showing results (311-320 of 362) with videos related to

Pageof 37
Sort By:
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|June 9, 2024
Application of REVEAL Lite 2 and COMPERA 2.0 risk scores to patients with pulmonary arterial hypertension switching to riociguat in the REPLACE studyRaymond L Benza, Gérald Simonneau, Hossein-Ardeschir Ghofrani, et al.
The European Respiratory Journal|September 11, 2017
RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitorsMarius M Hoeper, Gérald Simonneau, Paul A Corris, et al.
JACC. Heart Failure|May 22, 2026
Refining the Definition for "Low Risk" in Pulmonary Arterial Hypertension: Time to Reduce Morbidity and MortalityCharles Fauvel, Priscilla Correa Jaque, Yongqi Liu, et al.
American Journal of Respiratory and Critical Care Medicine|February 17, 2009
Genetic risk factors for portopulmonary hypertension in patients with advanced liver diseaseKari E Roberts, Michael B Fallon, Michael J Krowka, et al.
Pulmonary Circulation|November 18, 2021
TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertensionRobert P Frantz, Raymond L Benza, Richard N Channick, et al.
Pulmonary Circulation|October 11, 2024
PPARγ/ETV2 axis regulates endothelial-to-mesenchymal transition in pulmonary hypertensionDong Hun Lee, Minseong Kim, Sarah S Chang, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|November 5, 2018
Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 studyAdaani Frost, Munir Janmohamed, Jason S Fritz, et al.
Journal of the American College of Cardiology|September 2, 2024
Impact of Renal and Liver Function on Clinical Outcomes Following Tricuspid Valve Transcatheter Edge-to-Edge RepairUlrich P Jorde, Raymond Benza, Patrick M McCarthy, et al.
Circulation|March 19, 2003
The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular AngiogenesisTimothy D Henry, Brian H Annex, George R McKendall, et al.
Circulation. Cardiovascular Quality and Outcomes|May 22, 2019
Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare DiseasesAdam Torbicki, Marisa Bacchi, Marion Delcroix, et al.
Pageof 37

Showing results (311-320 of 362) with videos related to

Sort By:
Pageof 37
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|June 9, 2024
Application of REVEAL Lite 2 and COMPERA 2.0 risk scores to patients with pulmonary arterial hypertension switching to riociguat in the REPLACE studyRaymond L Benza, Gérald Simonneau, Hossein-Ardeschir Ghofrani, et al.
The European Respiratory Journal|September 11, 2017
RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitorsMarius M Hoeper, Gérald Simonneau, Paul A Corris, et al.
JACC. Heart Failure|May 22, 2026
Refining the Definition for "Low Risk" in Pulmonary Arterial Hypertension: Time to Reduce Morbidity and MortalityCharles Fauvel, Priscilla Correa Jaque, Yongqi Liu, et al.
American Journal of Respiratory and Critical Care Medicine|February 17, 2009
Genetic risk factors for portopulmonary hypertension in patients with advanced liver diseaseKari E Roberts, Michael B Fallon, Michael J Krowka, et al.
Pulmonary Circulation|November 18, 2021
TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertensionRobert P Frantz, Raymond L Benza, Richard N Channick, et al.
Pulmonary Circulation|October 11, 2024
PPARγ/ETV2 axis regulates endothelial-to-mesenchymal transition in pulmonary hypertensionDong Hun Lee, Minseong Kim, Sarah S Chang, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|November 5, 2018
Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 studyAdaani Frost, Munir Janmohamed, Jason S Fritz, et al.
Journal of the American College of Cardiology|September 2, 2024
Impact of Renal and Liver Function on Clinical Outcomes Following Tricuspid Valve Transcatheter Edge-to-Edge RepairUlrich P Jorde, Raymond Benza, Patrick M McCarthy, et al.
Circulation|March 19, 2003
The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular AngiogenesisTimothy D Henry, Brian H Annex, George R McKendall, et al.
Circulation. Cardiovascular Quality and Outcomes|May 22, 2019
Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare DiseasesAdam Torbicki, Marisa Bacchi, Marion Delcroix, et al.
Pageof 37